| No. of patients (incidence rate/100 person-years) |
Hazard ratio (95% CI) | Interaction P value |
|||
|---|---|---|---|---|---|
| Apixaban (n=38,756) |
Warfarin (n=35,051) |
||||
| All NVAF patients |
|
||||
| Stroke/SE | 562 (2.1) | 848 (3.1) |
|
0.75 (0.67-0.84) | --- |
| MB | 1431 (5.2) | 2530 (9.0) |
|
0.64 (0.59-0.68) | --- |
| Interaction analysis |
|
||||
| Stroke/SE |
|
||||
| Non-obese* | 411 (2.4) | 636 (3.7) |
|
0.72 (0.63-0.82) | |
| Obese (non-morbid)† | 139 (1.6) | 189 (2.2) |
|
0.82 (0.65-1.03) | .602 |
| Obese (morbid)‡ | 12 (0.9) | 24 (1.5) |
|
0.66 (0.32-1.33) | |
| MB |
|
||||
| Non-obese* | 1019 (5.9) | 1776 (10.1) |
|
0.64 (0.59-0.69) | .385 |
| Obese (non-morbid)† | 359 (4.1) | 668 (7.6) |
|
0.59 (0.51-0.68) | |
| Obese (morbid)‡ | 53 (4.0) | 86 (5.3) |
|
0.75 (0.52-1.07) | |
No head-to-head clinical trials have been conducted comparing the efficacy and safety of DOACs versus DOACs.
